Alexandra Brown

Aegiq is a UK based full-stack photonic quantum computing company. We work with customers in a wide range of industries, including defence, aerospace, cybersecurity and AI, to solve their most demanding computational challenges. Our integrated photonic approach offers speed, compactness and modularity with a clear path towards the fault tolerant era of large scale quantum computers.

Remedi Solutions is a healthcare company committed to helping improve transparency and care in care homes. Our model comprises of a pharmacy and single software solution. Our software, R360 is a fully integrated eMAR and Care Planning System and when linked to the automated dispensing technology in our pharmacy, this reduces the risk of errors in the dispensing process. Using an exclusive closed loop system with a transparent 3-way check, ensuring what you order from the GP surgery is what you receive from our pharmacy and thus reducing check-in times. Our aim is to guide care homes on their journey to excellence in medicines management. Using the enter once, reuse many times method.

MediSieve is a London biotech start-up developing Magnetic Haemofiltration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. A unique, lifesaving and often cost-saving solution, there are several multi-billion-dollar markets available for this product in oncology, infectious diseases, auto-immune diseases, poisoning, drug overdose and others. Magnetic Haemofiltration has already been shown to rapidly, specifically, and effectively remove IL-6 from human plasma. The technology has completed pre-clinical validation, including animal studies, and is expected to start clinical studies in Q2 2022. MediSieve has raised £4M in equity funding and over £4M in non-dilutive grants. Seeking a further £8M at Series A to support pivotal clinical trials and regulatory approvals. EIS eligible. The company has been featured in numerous online and print media articles, including the Sunday Telegraph, Daily Mail, and Wired Magazine, and been winner or finalist in several start-up competitions such as Pitch@Palace, MassChallenge, OBN Awards, TCT Magazine Awards and CMS Healthcare Startup of the Year. Recently, our founder George Frodsham was awarded BBSRC Innovator of the Year and MIT Innovators Under 35.

Headquartered in London and with a regional office in Edinburgh, we are distinguished by the calibre and engagement of the 24Haymarket Investor Network. We follow a strict investment thesis with a focus on verticals in the nascent stages of high growth where we can leverage proprietary insight from our Investor Network. We focus on investing in companies that have demonstrated initial commercial traction. We adhere to an active investment philosophy with a right to a board seat in each investment we pursue combined with an involved post-investment model.

Aegiq is a UK based full-stack photonic quantum computing company. We work with customers in a wide range of industries, including defence, aerospace, cybersecurity and AI, to solve their most demanding computational challenges. Our integrated photonic approach offers speed, compactness and modularity with a clear path towards the fault tolerant era of large scale quantum computers.

Remedi Solutions is a healthcare company committed to helping improve transparency and care in care homes. Our model comprises of a pharmacy and single software solution. Our software, R360 is a fully integrated eMAR and Care Planning System and when linked to the automated dispensing technology in our pharmacy, this reduces the risk of errors in the dispensing process. Using an exclusive closed loop system with a transparent 3-way check, ensuring what you order from the GP surgery is what you receive from our pharmacy and thus reducing check-in times. Our aim is to guide care homes on their journey to excellence in medicines management. Using the enter once, reuse many times method.

MediSieve is a London biotech start-up developing Magnetic Haemofiltration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. A unique, lifesaving and often cost-saving solution, there are several multi-billion-dollar markets available for this product in oncology, infectious diseases, auto-immune diseases, poisoning, drug overdose and others. Magnetic Haemofiltration has already been shown to rapidly, specifically, and effectively remove IL-6 from human plasma. The technology has completed pre-clinical validation, including animal studies, and is expected to start clinical studies in Q2 2022. MediSieve has raised £4M in equity funding and over £4M in non-dilutive grants. Seeking a further £8M at Series A to support pivotal clinical trials and regulatory approvals. EIS eligible. The company has been featured in numerous online and print media articles, including the Sunday Telegraph, Daily Mail, and Wired Magazine, and been winner or finalist in several start-up competitions such as Pitch@Palace, MassChallenge, OBN Awards, TCT Magazine Awards and CMS Healthcare Startup of the Year. Recently, our founder George Frodsham was awarded BBSRC Innovator of the Year and MIT Innovators Under 35.

Headquartered in London and with a regional office in Edinburgh, we are distinguished by the calibre and engagement of the 24Haymarket Investor Network. We follow a strict investment thesis with a focus on verticals in the nascent stages of high growth where we can leverage proprietary insight from our Investor Network. We focus on investing in companies that have demonstrated initial commercial traction. We adhere to an active investment philosophy with a right to a board seat in each investment we pursue combined with an involved post-investment model.

Accenture helps the world’s leading enterprises reinvent by building their digital core and unleashing the power of AI to create value at speed for organizations across industries. Our strategy is to be the reinvention partner of choice for our clients and lead in the safe, widespread adoption of AI, and to be the most client-focused, AI-enabled, great place to work in the world. We bring together the talent of our approximately 786,000 people with proprietary assets and platforms, deep process and industry expertise, and leading ecosystem relationships to deliver end-to-end solutions and measurable outcomes at scale. Through our Reinvention Services, we offer broad expertise across Cybersecurity, Digital Core, Finance, Industry and Enterprise, Song, Supply Chain and Engineering, and Talent, with advanced capabilities in AI and Data, Industry and Process, and Technology. We serve approximately 9,000 clients and generated approximately $70 billion in FY25 revenue. Visit us at accenture.com. This LinkedIn company page is moderated. When engaging with Accenture, we encourage everyone to: - Use common courtesy and be respectful of others. - Create your own original content and avoid content that you know to be fraudulent. - Never repost someone elses copyrighted work, unless you have permission. - Never post personal, identifying, or confidential information. We reserve the right to delete comments or posts we deem to be: - Profane, obscene, inappropriate, offensive, abusive material. - Spam, repeated comments and commercial messages and personal advertisements. - Discriminatory or that contain hateful speech of any kind regarding age, gender, race, religion, nationality, sexual orientation, gender identity or disability. - Threats; personal attacks; abusive, defamatory, derogatory, or inflammatory language; or stalking or harassment of any individual, entity or organization. - False, inaccurate, libelous, or otherwise misleading in any way.